Corcept Therapeutics Incorporated

As of June 30, 2026, Corcept Therapeutics Incorporated carries a market capitalization of 9.38B, placing it among publicly traded companies globally. Its enterprise value stands at 9.08B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Corcept Therapeutics Incorporated's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Corcept Therapeutics Incorporated has 107.92M shares outstanding.

As of June 30, 2026, Corcept Therapeutics Incorporated trades at a trailing price-to-earnings ratio of 164.29. The price-to-sales ratio is 10.91, and the price-to-book ratio stands at 13.30.

As of June 30, 2026, Corcept Therapeutics Incorporated trades at an EV/EBITDA multiple of 1,029.46 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 10.94 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 1,418.42 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.08B versus a market cap of 9.38B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Corcept Therapeutics Incorporated maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Corcept Therapeutics Incorporated posted a return on equity (ROE) of 8.23, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 6.53, measuring how efficiently the asset base is converted into earnings. The company generates approximately 1.24M in revenue per employee across its workforce of 672.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.11 indicates how many times Corcept Therapeutics Incorporated sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Corcept Therapeutics Incorporated recorded an income tax benefit of -28.81M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 26.37M, leaving 55.18M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Corcept Therapeutics Incorporated's stock has gained approximately 45.96% over the past 52 weeks. The 50-day moving average sits at 115.70, while the 200-day moving average is 73.30.

Over the twelve months ended June 30, 2026, Corcept Therapeutics Incorporated generated 830.81M in revenue and converted that into 55.18M in net income, yielding earnings per share of 0.48. EBITDA reached 8.83M, while operating income came in at 6.41M.

As of June 30, 2026, Corcept Therapeutics Incorporated holds 308.20M in cash and equivalents against 9.42M in total debt, resulting in a net debt position of -111.04M. Total book value stands at 705.78M, with working capital of 285.87M providing operational flexibility.

Corcept Therapeutics Incorporated produced 109.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.78M in capital expenditures, free cash flow totaled 106.92M - equivalent to 1.03 per share.

Over the twelve months ended June 30, 2026, Corcept Therapeutics Incorporated posted a gross margin of 98.30, reflecting its pricing power and cost economics. The operating margin of 0.77 and net profit margin of 6.64 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 1.06, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Corcept Therapeutics Incorporated shareholders.

As of June 30, 2026, Corcept Therapeutics Incorporated has an Altman Z-Score of 33.15, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.